Echodyne Announces New Longer-Range 4D Radar, EchoShield
12.10.2021 14:00:00 CEST | Business Wire | Press Release
Echodyne, the radar platform company, announced today the newest addition to its market-leading portfolio of radars - EchoShield. Designed from the ground-up to set a new price-performance standard for mid-range radars, EchoShield is an advanced software-defined multi-mission radar for a wide variety of commercial, defense, and government use cases.
EchoShield’s development has been informed by hundreds of customers and applications across multiple industries. The radar’s architecture builds upon the field-proven success of Echodyne’s proprietary metamaterials electronically scanned array (MESA®) radars that are in use across a wide range of applications, such as counter-UAS, border and base security, force protection, critical infrastructure security, intelligence, surveillance, and reconnaissance, UAV detect and avoid, and autonomous ground vehicles.
A pulse-Doppler cognitive 4D radar, EchoShield combines ultra-precise electronically scanned array (ESA) beamforming and real-time dynamic waveform synthesis to deliver sub-degree tracking accuracy on hundreds of objects across a broad 3D field of view. EchoShield’s cognitive search capabilities integrate onboard or offboard data stores to adapt and direct radar resources when and where required in order to deliver the right data and detail at the right time. Whether using the radar’s significant onboard processing capabilities or ingesting data-rich range-doppler spectrograms into offboard compute, EchoShield’s SDK enables deep integration and multi-sensor fusion.
EchoShield is designed to be software-optimized to mission profiles that align powerful dynamic radar resources with unique customer requirements to deliver superior radar performance. Based on market demand, the initial software release prioritizes a counter-UAS mission and excels at detecting, tracking, and classifying any uncrewed aircraft, including low slow and small drones even in dense urban environments. Further releases will match radar resources with customer demand in dozens of applications and markets.
“Radar is a fundamental sensor for a wide range of commercial and government applications, but achieving high performance at reasonable cost, size, weight and power (C-SWaP) has always been a challenge,” said Eben Frankenberg, CEO of Echodyne. “Our customers have challenged us with certain radar performance attributes and EchoShield has been designed to meet these demanding requirements. Our customers are lining up for first units and already discussing production volume, so we’re very pleased with the market reception.”
EchoShield is designed to operate in the Ku band, with radiolocation service at 15.7-16.6 GHz and radionavigation at 15.4-15.7 GHz, and is commercially exportable. Its features include:
- 130° azimuth x 90° elevation field of regard (fully customizable)
- 0.5° tracking accuracy in azimuth and elevation, with very low track splitting/dropping
- Powerful UAV classification with low false-alarms and near-zero false-negatives
- Cognitive search capabilities integrate onboard or offboard data
-
Average tracking ranges for counter-UAS mission:
- Group 1 (-20 to -10 dBsm): 2.7 to 4.8 km
- Group 2 (-10 to -5 dBsm): 4.8 to 6.4 km
- Group 3 (-5 to 5 dBsm): 6.4 to 11.4 km
“Our breakthrough Metamaterial-ESA technology unlocks a level of beamforming previously only available with large ultra-expensive AESA’s with hundreds of channels,” said Tom Driscoll, CTO of Echodyne. “EchoShield combines this precise beamforming with modern fully-adaptive cognitive-radar approaches and intelligent control software, and the result is a radar with best-in-class detection, tracking, and classification performance.”
For additional details and technical specifications, please visit our website at echodyne.com.
This device has not been authorized as required by the rules of the Federal Communications Commission. This device is not, and may not be, offered for sale or lease, or sold or leased, until authorization is obtained.
About Echodyne
Echodyne, the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically scanned array radars are used by defense and government agencies, autonomous developers, and security integrators for counter-UAS, borders and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Vulcan Capital, Vanedge Capital, and Lux Capital among others. For more information, please visit: Echodyne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005313/en/
Contact information
John O’Brien
echodyne@strangebrewstrategies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
